SCHEMBL31052237

SCHEMBL31052237

Clc1cc2c(c(N3CCNCC3)c1)OC(Cl)CO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 6/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
HTR6 P50406 7/20 0.39
HTR3E A5X5Y0 3/20 0.39
HTR3B O95264 3/20 0.39
HTR3A P46098 3/20 0.39
HTR3D Q70Z44 3/20 0.39
HTR3C Q8WXA8 3/20 0.39
HTR1A P08908 2/20 0.34
SIGMAR1 Q99720 3/20 0.34
HTR2A P28223 2/20 0.34
DRD2 P14416 2/20 0.34
DRD3 P35462 2/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31051743 0.89 ADRB1 (0.41) ADRB1CHRM2CHRM4CHRM1CHRM3
SCHEMBL31051943 0.80 ADRB1 (0.61) ADRB1HTR6HTR3EHTR3BHTR3A
SCHEMBL1455855 0.79 ADRB1 (0.59) ADRB1CHRM2CHRM4CHRM1CHRM3
Hydrochloric Acid SCHEMBL4171025 0.77 ADRB1 (0.57) ADRB1CHRM2CHRM4CHRM1CHRM3
SCHEMBL31052008 0.74 DRD2 (0.47) ADRB1HTR6HTR3EHTR3BHTR3A
SCHEMBL31052240 0.74 ADRB1 (0.44) ADRB1HTR6HTR3EHTR3BHTR3A
SCHEMBL31052018 0.73 HTR2C (0.42) ADRB1HTR6HTR3EHTR3BHTR3A
SCHEMBL31051894 0.71 ADRB1 (0.61) ADRB1HTR6HTR3EHTR3BHTR3A
SCHEMBL31051841 0.70 HTR6 (0.41) ADRB1HTR6HTR3AHTR1ASIGMAR1
SCHEMBL31052101 0.70 HTR6 (0.38) ADRB1HTR6SIGMAR1HTR2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4678188-A1 PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS Ohnishi, Arata (JP) 2026-01-14 EP disclosed
WO-2024185842-A1 PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS 国立大学法人島根大学 2024-09-12 WO disclosed